Small Intestinal Lymphoma
Associated Genetic Biomarkers
NCI Definition: A non-Hodgkin or Hodgkin lymphoma that arises from the small intestine. 
There is 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are completed or closed. Of the trial that contains small intestinal lymphoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
MYC is the most frequent gene inclusion criterion for small intestinal lymphoma clinical trials .
Autologous hematopoietic stem cell transplantation, carmustine, and cyclophosphamide are the most common interventions in small intestinal lymphoma clinical trials.
Significant Genes in Small Intestinal Lymphoma
MYC is an inclusion eligibility criterion in 1 clinical trial for small intestinal lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and small intestinal lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.